Maria Magdalena Montt-Guevara

Dr. Maria Magdalena Montt-Guevara

Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Tuscany, Italy
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 June 2008 in Cell Stress and Chaperones
Verified
Journal Article
Open access
PDF file
MFMariel A. Fanelli
Mariel A. Fanelli
MMMaria Magdalena Montt-Guevara
Maria Magdalena Montt-Guevara
ADAngela M. Diblasi
Angela M. Diblasi
FGFrancisco E. Gago
Francisco E. Gago
OTOlga Tello
Olga Tello
DCDaniel R. Ciocca
Daniel R. Ciocca
The cadherin–catenin proteins have in common with heat shock proteins (HSP) the capacity to bind/interact proteins of other classes. Moreover, there are common molecular pathways that connect the HSP response and the cadherin–catenin protein system. In the present study, we have explored whether in breast cancer the HSP might interact functionally with the cadherin–catenin cell adhesion system. β-Catenin was immunoprecipitated from breast cancer biopsy samples, and the protein complexes isolated in this way were probed with antibodies against HSP family members. We are thus the first to demonstrate a specific interaction between β-catenin and Hsp27. However, β-catenin did not bind Hsp60, Hsp70, Hsp90, gp96, or the endoplasmic reticulum stress response protein CHOP. To confirm the finding of Hsp27-β-catenin interaction, the 27-kDa immunoprecipitated band was excised from one-dimensional polyacrylamide gel electrophoresis gels and submitted to liquid chromatography–tandem mass spectrometry with electrospray ionization, confirming a role for Hsp27. In addition, β-catenin interacted with other proteins including heat shock transcription factor 1, P-cadherin, and caveolin-1. In human breast cancer biopsy samples, β-catenin was coexpressed in the same tumor areas and in the same tumor cells that expressed Hsp27. However, this coexpression was strong when β-catenin was present in the cytoplasm of the tumor cells and not when β-catenin was expressed at the cell surface only. Furthermore, murine breast cancer cells transfected with hsp25 showed a redistribution of β-catenin from the cell membrane to the cytoplasm. When the prognostic significance of cadherin–catenin expression was examined by immunohistochemistry in breast cancer patients (n = 215, follow-up = >10 years), we found that the disease-free survival and overall survival were significantly shorter for patients expressing P-cadherin and for patients showing expression of β-catenin in the cytoplasm only (not at the cell surface). The interactions of β-catenin with Hsp27 and with HSF1 may explain some of the molecular pathways that influence tumor cell survival and the clinical significance in the prognosis of the breast cancer patients.

29 November 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
FFFranca Fruzzetti
Franca Fruzzetti
TFTiziana Fidecicchi
Tiziana Fidecicchi
MMMaria Magdalena Montt-Guevara
Maria Magdalena Montt-Guevara
TSTommaso Simoncini
Tommaso Simoncini
Estetrol (E4) is a natural estrogenic steroid that is normally produced by human fetal liver. Recent research has demonstrated that it is a potent, orally bioavailable, natural selective estrogen receptor modulator; it has a moderate affinity for both human estrogen receptor alpha (ERα) and ERβ, with a preference for ERα. Clinical studies have demonstrated possible use as an estrogen in combined oral contraceptives (COC). COCs containing E4 and drospirenone (DRSP) showed a high acceptability, tolerability, and user satisfaction also when compared to COCs containing ethinylestradiol (EE). E4/DRSP effectively inhibits ovulation, with a similar effect on endometrium thickness than that of EE-containing COCs. Low doses (15 mg) of E4 with DRSP (3 mg) showed promising results in term of bleeding pattern and cycle control, also when compared to other COCs containing synthetic estrogens. Moreover, the association has limited effects on serum lipids, liver, SHBG levels, and carbohydrate metabolism. This combination also could drive a lower risk of venous thromboembolism than EE-containing COCs. In this review, we will summarize the actual knowledge about the new E4-containing contraceptive. Further large-scale studies in the full target population are needed to provide more insights into the cardiovascular safety profile and user satisfaction of E4/DRSP.

1 April 2014 in Maturitas
Verified
Journal Article
Closed access
PCPeter Chedraui
Peter Chedraui
GEGustavo S. Escobar
Gustavo S. Escobar
FPFaustino R. Pérez-López
Faustino R. Pérez-López
GPGiulia Palla
Giulia Palla
MMMaria Magdalena Montt-Guevara
Maria Magdalena Montt-Guevara
TSTommaso Simoncini
Tommaso Simoncini

26 May 2014 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
MGMaria Silvia Giretti
Maria Silvia Giretti
MMMaria Magdalena Montt-Guevara
Maria Magdalena Montt-Guevara
ECElena Cecchi
Elena Cecchi
Paolo MannellaPaolo Mannella
Paolo Mannella
GPGiulia Palla
Giulia Palla
TSTommaso Simoncini
Tommaso Simoncini
Estetrol (E4) is a natural human estrogen present at high concentrations during pregnancy. Due to its high oral bioavailability and long plasma half-life, E4 is particularly suitable for therapeutic applications. E4 acts as a selective estrogen receptor (ER) modulator, exerting estrogenic actions on the endometrium or the central nervous system, while antagonizing the actions of estradiol in the breast. We tested the effects of E4 on its own or in the presence of 17β-estradiol (E2) on T47-D ER+ breast cancer cell migration and invasion of three-dimensional matrices. E4 administration to T47-D cells weakly stimulated migration and invasion. However, E4 decreased the extent of movement and invasion induced by E2. Breast cancer cell movement requires a remodeling of the actin cytoskeleton. During exposure to E4, a weak, concentration-dependent, re-distribution of actin fibers toward the cell membrane was observed. However, when E4 was added to E2, an inhibition of actin remodeling induced by E2 was seen. Estrogens stimulate ER+ breast cancer cell movement through the ezrin–radixin–moesin family of actin regulatory proteins, inducing actin and cell membrane remodeling. E4 was a weak inducer of moesin phosphorylation on Thr558, which accounts for its functional activation. In co-treatment with E2, E4 blocked the activation of this actin controller in a concentration-related fashion. These effects were obtained through recruitment of estrogen receptor-α. In conclusion, E4 acted as a weak estrogen on breast cancer cell cytoskeleton remodeling and movement. However, when E2 was present, E4 counteracted the stimulatory actions of E2. This contributes to the emerging hypothesis that E4 may be a naturally occurring ER modulator in the breast.

10 February 2017 in Journal of Neurochemistry
Verified
Journal Article
Closed access
SMSimona Melfi
Simona Melfi
MMMaria Magdalena Montt-Guevara
Maria Magdalena Montt-Guevara
Veronica BonalumeVeronica Bonalume
Veronica Bonalume
MRMassimiliano Ruscica
Massimiliano Ruscica
ACAlessandra Colciago
Alessandra Colciago
Valerio MagnaghiValerio Magnaghi
Valerio Magnaghi